Variant · Expression
AR V9 EXPRESSION
CI-VAR-00004661Explore in graph →CIViC 2159
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28473535
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Prostate Neoplasm1 | ||||||||
| AR V9 EXPRESSION | Abiraterone Acetate | Predictive | E | Supports Resistance | 3 | submitted | EID5789Castration Resistant Prostate Cancer (CRPC) often develops after Androgen Deprivation Therapy due to reactivation of transcription of the Androgen Receptor (AR). Transcriptional reactivation can be du… (full text at CIViC) PMID 28473535 · Kohli et al., 2017 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.